Bajaj Healthcare has received an approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule.
Pimavanserin is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Pimavanserin, marketed globally as NUPLAZID®, has become a preferred treatment in the US antipsychotic segment. In a recent update, Acadia Pharmaceuticals announced that NUPLAZID®, along with its other brand DAYBUE , is projected to generate more than $1 billion in net sales in 2025.
The company has also extended offer for Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product's availability in the domestic market.